MARKET

GLMD

GLMD

Galmed Pharmaceu
NASDAQ
1.120
-0.010
-0.89%
After Hours: 1.090 -0.03 -2.68% 19:24 12/05 EST
OPEN
1.160
PREV CLOSE
1.130
HIGH
1.160
LOW
1.090
VOLUME
237.83K
TURNOVER
--
52 WEEK HIGH
3.610
52 WEEK LOW
0.7449
MARKET CAP
6.14M
P/E (TTM)
-0.3115
1D
5D
1M
3M
1Y
5Y
1D
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy
TipRanks · 3d ago
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
Benzinga · 3d ago
Galmed granted new Use Patent related to lead compound Aramchol
TipRanks · 3d ago
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Reuters · 3d ago
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
PR Newswire · 3d ago
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position
TipRanks · 6d ago
Galmed Pharmaceuticals Publishes 2025 Shareholder Letter
Reuters · 6d ago
Galmed Pharmaceuticals Reports Strong Cash Position and Expands Therapeutic Focus
Reuters · 6d ago
More
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

Webull offers Galmed Pharmaceuticals Ltd stock information, including NASDAQ: GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.